|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-11-11
|
|
pubmed:abstractText |
HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life. Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast cancer patients after trastuzumab-based therapies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:AllenK EKE,
pubmed-author:AogiKK,
pubmed-author:AraiTT,
pubmed-author:EllisC ECE,
pubmed-author:FujiwaraYY,
pubmed-author:GagnonR CRC,
pubmed-author:ItoYY,
pubmed-author:IwataHH,
pubmed-author:KatsuraKK,
pubmed-author:NakamuraSS,
pubmed-author:RaiYY,
pubmed-author:SasakiYY,
pubmed-author:TaguchiTT,
pubmed-author:TakashimaSS,
pubmed-author:ToiMM,
pubmed-author:TokudaYY,
pubmed-author:WakamatsuTT,
pubmed-author:WatanabeJJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
17
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1676-82
|
|
pubmed:dateRevised |
2010-11-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19844234-Adult,
pubmed-meshheading:19844234-Aged,
pubmed-meshheading:19844234-Antineoplastic Agents,
pubmed-meshheading:19844234-Breast Neoplasms,
pubmed-meshheading:19844234-Disease Progression,
pubmed-meshheading:19844234-Female,
pubmed-meshheading:19844234-Humans,
pubmed-meshheading:19844234-Japan,
pubmed-meshheading:19844234-Kaplan-Meier Estimate,
pubmed-meshheading:19844234-Middle Aged,
pubmed-meshheading:19844234-Quinazolines,
pubmed-meshheading:19844234-Receptor, erbB-2,
pubmed-meshheading:19844234-Tumor Markers, Biological,
pubmed-meshheading:19844234-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
|
|
pubmed:affiliation |
Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. toi@kuhp.kyoto-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
